Tarcocimab tedromer

替卓塔珂西单抗

Report date: 2026/04/29 20:02:18

Base Information

Drug NameTarcocimab tedromer
Drug Alias Name塔珂西单抗KSI-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody biopolymer conjugate (ABC)
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSlovakia +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesKodiak Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesBaker Bros Advisors LPKodiak Sciences Inc
Inactive CompaniesDmed Biopharmaceutical Co LtdKodiak Sciences China IncLifecore Biomedical Llc
Active IndicationsRetinal Vein OcclusionWet age-related macular degenerationMacular Edema +[4] 
Inactive IndicationsDiabetic macular oedema

Other Information

ATC CodeN/A
Related LinksN/A